Tey A, Schwarer J, Raffa R, Shi E, et al. High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma. Eur J Haematol 2023 Jan 19. doi: 10.1111/ejh.13928.
PMID: 36656100